Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study.

Abstract

BACKGROUND AND OBJECTIVE:

Low adherence to treatment is associated with poorer clinical outcome and greater healthcare resources utilization (HRU). Limited data are available on the extent of adherence to each individual antidepressant. The goal of this study was to compare the adherence rate to desvenlafaxine versus usual care with selective serotonin reuptake inhibitors (SSRI) and/or other serotonin-norepinephrine reuptake inhibitors (SNRI), in subjects with major depressive disorder (MDD).

METHODS:

Retrospective, multi-centric, observational study including 574 outpatients with MDD. Data were collected from mental and primary care centers. Adherence, persistence, effectiveness, and HRU was evaluated through multivariate regression models.

RESULTS:

At 12-months, adjusted adherence rate was higher with desvenlafaxine versus SNRI/SSRI, 67.9% versus 59.9% (OR 1.66, 95% CI 1.07-2.59, p = 0.024). Remission rate was numerically higher with desvenlafaxine versus SNRI/SSRI, 55.9% versus 50.1% (OR 1.35, 95% CI 0.93-1.98, p = 0.118), as well as treatment response, 76.5% in desvenlafaxine group versus 70.8% in SNRI/SSRI group (OR 1.25, 95% CI 0.82-1.90, p = 0.300). Medical visits use was higher in SNRI/SSRI than in desvenlafaxine group [9.8 (4.8) versus 9.1 (6.0), p = 0.019].

CONCLUSIONS:

Desvenlafaxine is significantly associated with a higher adherence rate at 12 months compared to usual care based on SSRI or other SNRI. This suggests that desvenlafaxine could improve disease management having a positive impact on disease-associated costs.

• Authors: Narcís Cardoner, Antoni Sicras-Mainar, Javier Rejas, Beatriz Armada
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 41 Issue 12 Pg. 1055-1066 (Dec 2021) ISSN: 1179-1918 [Electronic] New Zealand
• PMID: 34741760 (Publication Type: Journal Article, Observational Study)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Antidepressive Agents
• Serotonin Uptake Inhibitors
• Desvenlafaxine Succinate

Topics

• Antidepressive Agents (therapeutic use)
• Depressive Disorder, Major (drug therapy)
• Desvenlafaxine Succinate (therapeutic use)
• Humans
• Retrospective Studies
• Selective Serotonin Reuptake Inhibitors (therapeutic use)